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Abstract
Proteins of the nuclear envelope (NE) are associated with a range of inherited disorders, most commonly involving muscular
dystrophy and cardiomyopathy, as exemplified by Emery-Dreifuss muscular dystrophy (EDMD). EDMD is both genetically
and phenotypically variable, and some evidence of modifier genes has been reported. Six genes have so far been linked to
EDMD, four encoding proteins associated with the LINC complex that connects the nucleus to the cytoskeleton. However,
50% of patients have no identifiable mutations in these genes. Using a candidate approach, we have identified putative
disease-causing variants in the SUN1 and SUN2 genes, also encoding LINC complex components, in patients with EDMD and
related myopathies. Our data also suggest that SUN1 and SUN2 can act as disease modifier genes in individuals with co-
segregating mutations in other EDMD genes. Five SUN1/SUN2 variants examined impaired rearward nuclear repositioning
in fibroblasts, confirming defective LINC complex function in nuclear-cytoskeletal coupling. Furthermore, myotubes from a
patient carrying compound heterozygous SUN1 mutations displayed gross defects in myonuclear organization. This was
accompanied by loss of recruitment of centrosomal marker, pericentrin, to the NE and impaired microtubule nucleation at
the NE, events that are required for correct myonuclear arrangement. These defects were recapitulated in C2C12 myotubes
expressing exogenous SUN1 variants, demonstrating a direct link between SUN1 mutation and impairment of nuclear-
microtubule coupling and myonuclear positioning. Our findings strongly support an important role for SUN1 and SUN2 in
muscle disease pathogenesis and support the hypothesis that defects in the LINC complex contribute to disease pathology
through disruption of nuclear-microtubule association, resulting in defective myonuclear positioning.
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Introduction
The nuclear envelope (NE) is composed of the nuclear
membranes, nuclear lamina and nuclear pore complexes and
encloses the chromatin in eukaryotic cells. Lamin intermediate
filament proteins are the major structural components of the NE
and polymerize to form a fibrous meshwork that underlies the
nucleoplasmic face of the inner nuclear membrane. This nuclear
lamina is attached to the inner nuclear membrane through
interactions with multiple integral inner nuclear membrane (INM)
proteins [1]. Together, these proteins form a structural network
that plays a vital role in supporting the NE and maintaining
nuclear integrity, whilst also contributing to chromatin organiza-
tion and regulation of gene expression (reviewed in [2]).
Mutations in genes encoding NE proteins are associated with a
range of tissue-restricted inherited disorders that can affect striated
muscle, bone, fat or neurons and in some cases cause premature
ageing syndromes [3]. Most strikingly, different mutations in one
gene – the LMNA gene that encodes A-type nuclear lamins – can
cause many diseases, which have collectively been termed
laminopathies [4]. Diseases affecting striated muscle are the most
common of the laminopathies and include autosomal dominant
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and recessive Emery-Dreifuss muscular dystrophy (EDMD2 and
EDMD3, respectively; OMIM#181350), limb-girdle muscular
dystrophy (LGMD) type 2B and dilated cardiomyopathy and
conduction system disease (CMD) type 1A [5–8]. These diseases
share the common feature of cardiomyopathy, but EDMD and
LGMD also involve progressive muscle wasting and weakness. In
all cases, premature sudden death can result from cardiac
arrhythmia and conduction defects.
Striated muscle disease, in particular EDMD, can also be
caused by mutations in genes encoding other NE proteins. An X-
linked form of EDMD (EDMD1; OMIM#310300) is caused by
mutations in EMD, that encodes the integral INM protein emerin
[9]. Together, mutations in LMNA and EMD account for around
40% of cases of EDMD [10]. Rare mutations in the genes
encoding FHL1, TMEM43 (also named LUMA), nesprin-1 and
nesprin-2 have also been reported [11–13]. Interestingly, A-type
lamins, nesprins and emerin all interact with each other [14–16],
contributing to a network that connects the nuclear lamina to the
cytoskeleton, termed the LINC (Linker of Nucleoskeleton and
Cytoskeleton) complex [17]. Furthermore, interactions are often
perturbed by muscle disease-causing mutations, indicating that this
network of interactions plays an important role in muscle function
[12,18,19].
The central components of the LINC complex in mammals are
SUN and nesprin proteins that reside in the INM and outer
nuclear membrane (ONM), respectively. The conserved SUN and
KASH domains of the respective proteins interact in the
perinuclear space to form a bridge spanning the INM, perinuclear
space and ONM that connects the nuclear lamina to the
cytoskeleton. The nucleoplasmic N-termini of the SUN proteins,
SUN1 and SUN2, interact with the nuclear lamina, anchoring the
LINC complex at the NE [20–22]. In turn, the cytoplasmic
domains of the nesprins connect to the cytoskeleton. There are 4
nesprin isoforms encoded by different genes. Giant isoforms of
nesprins-1 and -2 contain an N-terminal calponin homology
domain responsible for actin binding [23,24] and linkage to the
centrosome through microtubules and their motor proteins [25].
Nesprin-3 connects to the cytoplasmic intermediate filament
network through interaction with plectin [26], whilst nesprin-4 is
specific to epithelial cells and connects the NE to microtubules via
the kinesin-1 motor protein [27].
There are several proposed mechanisms to explain the tissue
specificity of EDMD and other laminopathies, which centre
around the ‘‘gene expression’’ and ‘‘structural’’ hypotheses [28].
Current evidence strongly supports the ‘‘structural hypothesis’’,
which suggests that muscle-associated laminopathies primarily
result from weakening of the structural networks of the nuclear
lamina and cytoskeleton and the LINC complex that connects
these two networks [29]. Since myocytes are subject to recurrent
mechanical strain from contractile forces, weakening of these
structural networks renders the cells particularly susceptible to
damage. However, the LINC complex is also vital for correct
myonuclear positioning [30–33] and defects in this process are
implicated in impaired muscle function [34,35].
Despite the genetic studies so far carried out, causative
mutations have been identified in only approximately 50% of
EDMD and related muscle disease cases [10]. It is therefore highly
likely that mutations in additional genes contribute to the disease.
Furthermore, there is significant heterogeneity in disease severity
even within families carrying the same gene mutation [36–40],
which has led to the suggestion of modifier genes [41–43].
Given that SUN1 and SUN2 interact with at least four of the
known muscle disease-associated NE proteins and that these
interactions can be perturbed by disease-causing LMNA and
EMD mutations [44], we investigated whether the SUN1 and
SUN2 genes may also be mutated in some individuals. Screening
of the SUN1 and SUN2 genes in a large cohort of patients with
EDMD and phenotypically related myopathies identified SUN1
and/or SUN2 variants in several patients. Presence of SUN1 or
SUN2 variants correlated with increased disease severity in
patients with EDMD carrying mutations in other genes, thus
identifying SUN1 and SUN2 as modifiers of the EDMD disease
phenotype. We further provide evidence that these mutations
disrupt nuclear-cytoskeletal connection and nuclear positioning,
supporting the hypothesis that muscular dystrophies arise from
defective nuclear-cytoskeletal coupling.
Results
Screening SUN1 and SUN2 genes in a cohort of patients
with EDMD and related myopathies
We analyzed DNA from 175 unrelated patients with EDMD
and related myopathies, who had previously undergone screening
for mutations in the LMNA, EMD, SYNE1/SYNE2 alpha and
beta (encoding short isoforms of nesprin-1 and nesprin-2,
respectively) and FHL1 genes and in whom no causative mutation
had been found. These included both sporadic cases and index
patients from familial cases. Furthermore, there have been several
reports of modifiers of the phenotype of LMNA-linked muscle
diseases [41–43]. We therefore also screened EDMD patients
carrying identified LMNA, SYNE1/SYNE2 alpha and beta and
EMD mutations to determine whether mutation of SUN1 or
SUN2 may influence disease phenotype. Most individuals were of
Caucasian origin, except where otherwise stated.
The 23 exons of the SUN1 gene (see Figure S1) and 19 exons of
the SUN2 gene (ENSG00000100242, ENST00000405510),
including intron/exon boundaries and promoter regions were
analyzed. DNA was amplified using PCR and analyzed by direct
Sanger sequencing. In total, we found 34 single nucleotide
polymorphisms within the coding regions of SUN1 and SUN2,
18 of which were classified as rare, non-synonymous changes
following analysis of their frequencies in sequenced genome
Author Summary
Emery-Dreifuss muscular dystrophy (EDMD) is an inherited
disorder involving muscle wasting and weakness, accom-
panied by cardiac defects. The disease is variable in its
severity and also in its genetic cause. So far, 6 genes have
been linked to EDMD, most encoding proteins that form a
structural network that supports the nucleus of the cell
and connects it to structural elements of the cytoplasm.
This network is particularly important in muscle cells,
providing resistance to mechanical strain. Weakening of
this network is thought to contribute to development of
muscle disease in these patients. Despite rigorous screen-
ing, at least 50% of patients with EDMD have no
detectable mutation in the 6 known genes. We therefore
undertook screening and identified mutations in two
additional genes that encode other components of the
nuclear structural network, SUN1 and SUN2. Our findings
add to the genetic complexity of this disease since some
individuals carry mutations in more than one gene. We
also show that the mutations disrupt connections between
the nucleus and the structural elements of cytoplasm,
leading to mis-positioning and clustering of nuclei in
muscle cells. This nuclear mis-positioning is likely to be
another factor contributing to pathogenesis of EDMD.
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databases (Table S1, Figure S3). Three of these variants did not
segregate with disease in the respective families (Figure S2). In nine
unrelated families or sporadic cases, however, we identified 10 rare
non-synonymous variants in SUN1 and SUN2 for which we have
obtained evidence of pathogenic effects, as deduced from genetic,
phenotypic and/or functional data (Figure 1A).
Putative disease-associated SUN1 and SUN2 variants in
patients with EDMD-like phenotypes
We identified 5 rare, non-synonymous SUN1 and/or SUN2
variants in 3 individuals who lacked mutations in other genes but
had EDMD or related myopathy phenotypes (Table 1). Sporadic
patient MD-11 carried a single SUN2 p.R620C sequence
variation. We had no access to DNA from family members for
this patient, but the high degree of evolutionary conservation of
R620 is supportive of disease-association (Figure S3). Patient MD-
1 carried compound heterozygous SUN1 p.G68D and p.G338S
variants. For patient MD-1 we had access to DNA from family
members and observed apparent recessive inheritance, with one
mutation coming from each of the unaffected parents (Figure 1B).
SUN1 p.G338S was also present in the reference population at
low frequency (see Table S1). These residues are located within the
Figure 1. SUN1 and SUN2 variants identified and associated family pedigrees. (A) Schematic diagram of the SUN1 and SUN2 protein
domain organization and locations of disease-associated variants identified in our cohort. Mutation SUN1 M50T, indicated in purple, did not disrupt
LINC complex function in migration assays and thus may not be truly disease-causing. The mapped lamin A/C (green) and emerin (orange) binding
sites, located in the nucleoplasmic N-terminal domain, are indicated. Regions of high hydrophobicity and the transmembrane domain are shown in
grey and black, respectively. Coiled-coil domains responsible for oligomerization (blue) and the highly conserved SUN domain (red), found within the
luminal C-terminal domain, are also indicated. (B) Pedigree with recessive inheritance of compound heterozygous SUN1 variants. (C) Pedigrees where
severely affected index cases carry SUN1 and/or SUN2 variants in combination with other gene mutations. Filled circles/squares indicate affected
females/males. Circles containing a dot, in family 3, indicate unaffected female carriers of the X-linked EMD mutation. Arrows indicate index patients.
doi:10.1371/journal.pgen.1004605.g001
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poorly conserved N-terminal domain of the protein and, in this
context, are moderately conserved (Figure S3), but functional data
presented below present compelling evidence of the involvement
of both mutations in disease causation. Sporadic patient MD-12
carried heterozygous changes in both SUN1 and SUN2, encoding
SUN1 p.W377C and SUN2 p.E438D, respectively. E438 is
conserved in mammals, whilst W377 is conserved across all species
examined (Figure S3).
SUN1 and SUN2 variants with disease modifying effects in
patients with co-segregating mutations in other genes
Because patients with EDMD-like phenotypes exhibit variable
disease severity that could be explained by mutations or
polymorphisms in additional genes, we screened for SUN1 and
SUN2 variants in patients with known mutations in causative
genes. SUN1 or SUN2 variants were indeed present in some
patients from families with LMNA or X-linked EMD mutations
(Table 2; Figure 1C). These sequence changes correlated with
increased disease severity. In one example, a SUN1 p.A203V
polymorphism in patient MD-3 co-segregated with a previously
reported EMD p.L84Pfs*6 mutation in two brothers with
unusually severe EDMD (Figure 1C, Family 3) [39]. The EMD
p.L84Pfs*6 mutation, which abolishes emerin expression, has been
reported in an unrelated family, where the course of the disease
was significantly milder EDMD with later age of onset and no loss
of ambulation [45]. Another unrelated patient carrying EMD
p.L84Pfs*6 was included in this study but no SUN1 or SUN2
variants were found and their phenotype was similar to that
described by Manilal et al. [45]. In another case, the SUN1
p.G76A mutation, when combined with EMD p.A56Pfs*9 in a
previously described Korean patient (MD-4), led to a very severe
clinical picture with complete atrioventricular block requiring pace
maker implantation at age 14 years [46]. Similarly, SUN1
p.W377C was detected in combination with LMNA p.R453W
in patient MD-5. This individual had severe disease and died early
at the age of 34 years from heart failure. The patient’s son,
carrying LMNA p.R453W only, did not show clinical signs of
contractures or muscular weakness at age 10 years. LMNA
p.R453W is a common EDMD-associated LMNA mutation and is
generally not associated with severe cardiac disease, suggesting
that, in patient MD-5, SUN1 p.W377C had a modifying effect to
increase disease severity [47,48]. The same SUN1 p.W377C
variant was detected in patient MD-12, who had an EDMD-like
phenotype but did not have mutations in EMD or LMNA but
carried a concurrent SUN2 p.E438D variant, as described above.
We detected SUN2 mutations in combination with LMNA
mutations in two additional index cases. Patient MD-6 carried
LMNA p.T528K and SUN2 p.A56P, whilst patient MD-7 carried
LMNA p.R98P and SUN2 p.V378I (Table 2; Figure 1C). In both
cases, the LMNA mutation had arisen de novo, whilst the SUN2
mutation was inherited from an unaffected parent. Again, the
disease expression in both index patients was more severe than is
typical for EDMD [49,50], with early onset at age 1 and 4 years,
respectively, and early heart involvement including heart trans-
plantation before age 20 years (Table 2).
We also identified two SUN2 variants, encoding variants
p.M50T and pV378I, in patient MD-2 who had hypertrophic
cardiomyopathy and also carried a mutation in MYBPC3
(p.G148R), which encodes a myosin binding protein. The same
MYBPC3 mutation was previously reported in a Dutch family,
where a severely affected index patient had compound heterozy-
gous mutations in MYCBP3 but other family members carrying
only p.G148R were either asymptomatic or developed cardiomy-
opathy late in life [51]. This MYBPC3 mutation was present in
both patient MD-2 and his father (Figure 1C; S. Waldmueller,
personal communication). Patient MD-2 presented as a 6 month-
old boy with hypertrophic cardiomyopathy and died at 16 years
from heart failure. His father, who carries the SUN2 p.M50T
variant but not p.V378I, is asymptomatic. Thus, the SUN2
p.V378I variant appears to have a dramatic effect on disease
severity. Notably, this variant is present in the reference
population at low frequency (see Table S1), suggesting that it
may be a relatively common genetic modifier of inherited
cardiomyopathy.
SUN1 and SUN2 disease-associated variants disrupt
centrosome reorientation and nuclear movement in
NIH3T3 fibroblasts
Our genetic results suggest that mutations or polymorphisms in
SUN1 and SUN2 may cause muscular dystrophy and act as
modifiers of EDMD and cardiomyopathy. To obtain additional
evidence that these variants play a role in pathophysiology, we
examined the effects of several variants on a known function of the
LINC complex, namely centrosome orientation and nuclear
movement in migrating cells. SUN2, along with the nesprin-2G
isoform, assembles into transmembrane actin-associated nuclear
(TAN) lines that couple actin cables to the nucleus to move it
rearward and reorient the centrosome toward the leading edge in
migrating NIH3T3 fibroblasts [52,53]. While SUN1 is not in TAN
lines, it also functions in connecting the nucleus to the cytoskeleton
via the LINC complex.
We expressed three myc-SUN1 and three myc-SUN2 variants in
NIH3T3 fibroblasts at the edge of a wounded monolayer by DNA
microinjection and stimulated nuclear movement and centrosome
reorientation with the serum factor, lysophosphatidic acid (LPA).
Upon stimulation, non-expressing NIH3T3 cells or NIH3T3 cells
exogenously expressing wild-type (WT) SUN1 or SUN2, as well as
the variant SUN2 M50T, reoriented their centrosomes (Figure 2A–
B). Notably, SUN2 p.M50T did not appear to influence disease
Table 1. Putative disease-causing variants in SUN1 and SUN2 in patients with EDMD-like phenotypes.
Family Index case SUN1 variant SUN2 variant Other mutations Disease phenotype
1 MD-1 p.G68D p.G338S none none Male; age at onset 10 years; mild muscle weakness; rigid spine;
serum creatine kinase elevation 6X; no cardiac involvement; last
clinical examination at age 10 years; sporadic case.
11 MD-11 none p.R620C none Sporadic EDMD-related myopathy, no other clinical information
available.
12 MD-12 p.W377C p.E438D none Heart rhythm disturbances at age 34 years; partial lipodystrophy
on left lower leg; sporadic case
doi:10.1371/journal.pgen.1004605.t001
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severity in family 2. In contrast, cells expressing the putative disease-
causing SUN1 variants, G68D, G338S or W377C, inhibited
centrosome reorientation by blocking rearward positioning of the
nucleus (Figure 2A–B). Similarly, cells expressing SUN2 A56P or
R620C failed to reorient their centrosome due to an inability to
position their nuclei rearward of the cell centroid (Figure 2A–B). All
of the expressed SUN1 and SUN2 variants had a normal nuclear
localization similar to the wild-type proteins (Figure 2A). The
centrosome orientation defect in cells expressing the SUN variants
occurred due to defective rearward nuclear movement and not
disruption of positioning of the centrosome at the cell centroid
(Figure 2C). Hence, five putative disease-causing or disease-modify-
ing SUN variants blocked rearward nuclear movement in migrating
NIH3T3 fibroblasts and it can be concluded that these mutants
disrupt LINC complex function.
Expression of LINC complex components is altered in
patient myoblasts with compound heterozygous SUN1
mutations
Having established that some of the variants identified in our
patient cohort disrupted LINC complex function in fibroblasts, we
next wished to examine their role in muscle cells. We were able to
obtain primary myoblasts from patient MD-1, carrying compound
heterozygous SUN1 p.G68D/p.G338S variants. To gain initial
insight into the cellular effects of these mutations, we examined
expression of LINC complex components and known SUN1 binding
partners in the myoblasts by immunofluorescence microscopy. Since
nesprin-1 is not significantly expressed in myoblasts [54,55] (Figure
S4), we stained for nesprin-2, lamin A/C, emerin, SUN1 and SUN2.
No obvious defects in localization of SUN1, SUN2 or their
interacting NE partners were observed, but expression of SUN1
and nesprin-2 at the NE was enhanced in the patient myoblasts
(Figure 3A–B). Quantification of fluorescence intensity suggested that
their expression was increased approximately 2-fold.
Since fluorescence intensity does not always provide an accurate
reflection of total protein levels, we then examined total protein
expression level by Western blot and found that SUN1 levels were
elevated 8-fold in the patient versus control myoblasts (Figure 3C,E).
Consistent with the fact that SUN proteins form complexes with, and
are responsible for anchoring of nesprins in the ONM, we also
observed a 4-fold increase in expression of the intermediate-sized
muscle-enriched isoforms of nesprin-2 [55] in the patient myoblasts
(Figure 3D–E). However, it remains possible that the bands observed
are degradation products of nesprin-2 giant. In contrast, levels of
SUN2, lamin A/C and emerin were not significantly altered in the
patient cells (Figure 3C,F). To exclude the possibility that the observed
changes were due to different levels of background differentiation in the
control and patient cultures, we quantified expression of myogenin, an
early marker of myogenic differentiation, and found no detectable level
in either culture (data not shown).
Table 2. SUN1 and SUN2 variants with disease-modifying effects in patients with MYBPC3, EMD and LMNA mutations.
Family Index case SUN1 variant SUN2 variant Other mutations Disease phenotype
2 MD-2 none p.M50T p.V378I MYBPC3 p.G148R Male; age at onset 6 months; hypertrophic cardiomyopathy; at
age 9 years ECG showed cardiac arrhythmia, supraventricular
extrasystols, Echocardiogram: right ventricular septum
hypertrophy, first degree atrioventricular block; no muscular
weakness or dystrophy; sinus tachycardia and bradycardia, mild
left ventricular functional impairment; died at age16 years from
heart failure; sporadic case.
3 MD-3 p.A203V none EMD p.L84Pfs*6 Male; age at onset 2 years; severe contractures of neck,
thoracolumbar spine, elbows, and Achilles tendons; Achillotomia
at age 6; loss of ambulation at age 15; moderate to severe muscle
weakness; left anterior hemi-block and ventricular ectopy at age
23; ventricular dilation at age 33; X-linked EDMD [39].
4 MD-4 p.G76A none EMD p.A56Pfs*9 Male; age of onset 1 year, wasting and weakness of shoulder
girdle and limb-girdle muscles; at age 14 severe contractures of
neck, elbow and Achilles tendons, tendon reflexes absent; at age
14 dilated right atrial and ventricular dilation, atrial fibrillation,
complete AV block and junctional escape rhythm; pacemaker
since age 14; CK elevation 4X; X-linked EDMD [46].
5 MD-5 p.W377C none LMNA p.R453W Male; age of onset 8 years; slowly progressive humero-peroneal
muscular weakness; since age 14 rigid spine, contractures of
elbow and Achilles-tendons; at age 25 cardiac disturbances; AV-
block III; heart pacemaker at age 31; died at age 34 of heart
failure; autosomal dominant EDMD.
6 MD-6 none p.A56P LMNA p.T528K Male; age at onset 1 year; delayed early childhood developmental
mile stones; later difficulties in climbing stairs, muscular
weakness; at age 15 tachycardia, extrasystols; at age 17 intra-
ventricular cardiac conduction defects, contractures of elbow and
Achilles tendons; proximal humero-peroneal muscle atrophy,
rigid spine, Gower’s maneuver; CK elevated 3–5X; de novo LMNA
mutation leading to sporadic EDMD.
7 MD-7 none p.V378I LMNA p.R99P Female; age of onset 4 years, diffuse muscular weakness; later
bilateral contractures of the elbows and ankles, dilated
cardiomyopathy, first degree atrioventricular block; at age 14
heart pacemaker; histopathology showed fibrosis of the heart
muscle; at age 15 heart transplantation; de novo LMNA mutation
leading to sporadic EDMD.
doi:10.1371/journal.pgen.1004605.t002
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To address the mechanism of SUN1 elevation in the patient
myoblasts, we examined SUN1 mRNA levels by qPCR and found no
significant increase in mRNA level compared to the control,
indicating that the p.G68D/p.G338S SUN1 variants do not lead
to increased mRNA levels (Figure S4). However, in analyzing mRNA
levels of other LINC complex-associated proteins, we observed a
statistically significant increase in expression of LMNA, SUN2,
SYNE1 and SYNE2. In contrast, EMD (encoding emerin) expression
was decreased in the patient relative to control myoblasts (Figure S4).
SUN1 interaction with emerin is impaired in MD-1
myoblasts
One hypothesis to explain NE-associated muscle diseases is the
‘‘structural hypothesis’’, which suggests that muscle damage occurs
due to weakening of the protein interaction network supporting
the NE [28,56]. To determine whether muscle disease-associated
SUN1 alterations disrupt interactions with other LINC complex
components, we performed immunoprecipitation with anti-SUN1
antibodies on protein extracts from control and patient MD-1
myoblasts and detected co-precipitating proteins. We observed a
reproducible reduction in SUN1 interaction with emerin in the
patient myoblasts, whilst interaction with lamin A/C was not
obviously perturbed (Figure 4A–B). Consistent with the enhanced
recruitment of nesprin-2 to the NE, interaction of SUN1 with
nesprin-2 was also maintained in the MD-1 myoblasts (Figure 4C).
Larger isoforms of nesprin-2 were enriched in the immunopre-
cipitate compared to the initial lysates, indicating a preferential
interaction of SUN1 with these less abundant isoforms. Thus, the
Figure 2. SUN1 and SUN2 variants disrupt nuclear-cytoskeletal coupling in NIH3T3 fibroblasts. (A) Representative immunofluorescence
micrographs of LPA-stimulated NIH3T3 fibroblasts expressing SUN1 or SUN2 wild-type (WT) or variant proteins. Cells were immunostained for myc
(green), tubulin (red) and DAPI (blue). Location of centrosome (arrows) was determined by the center of microtubule array. Bar, 20 mm. (B)
Quantification of centrosome reorientation in LPA-stimulated NIH3T3 fibroblasts expressing the indicated SUN variants. Significant differences are
indicated by * with a,0.05 based on Student’s t-test when the sample is compared to non-expressing NIH3T3 fibroblasts. (C) Quantification of
nucleus and centrosome position relative to the cell centroid in NIH3T3 fibroblasts expressing the indicated SUN variants. Positive values are toward
the leading edge, negative values toward the cell rear. Data are from at least three independent experiments for each sample. Significant differences
are indicated by * with a,0.05 based on Student’s t-test when the sample is compared to non-expressing NIH3T3 fibroblasts.
doi:10.1371/journal.pgen.1004605.g002
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Figure 3. Expression of LINC complex proteins is increased in patient MD-1 (SUN1 p.G68D/p.G338S) myoblasts. (A) Control and MD-1
myoblasts were fixed in methanol and analysed by immunofluorescence microscopy using SUN1, SUN2, emerin, nesprin-2G and lamin A/C
antibodies, as indicated, together with DAPI staining of DNA. Scale bar, 22 mm. (B) Mean fluorescence intensity of SUN1, SUN2, emerin, nesprin 2 and
SUN1 and SUN2 Variants in Muscular Dystrophies
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SUN1 p.G68D/p.G338S variants in patient MD-1 appear to
specifically disrupt interaction with emerin.
We confirmed defective interactions with emerin in HEK293
cells transiently expressing GFP-emerin and myc-SUN1 con-
structs. SUN1 was immunoprecipitated using anti-myc antibodies
and co-precipitating GFP-emerin detected by Western blotting.
We observed a significant reduction in interaction of emerin with
both SUN1 G338S and W377C, whilst there was only a modest
lamin A/C was measured in individual DAPI-stained nuclei using an Olympus Scan‘R screening station and analysed using Scan‘R analysis software.
The results are presented as mean 6 S.E. of 1000 cells taken from at least 3 independent experiments. **P#0.05. Significant P-value for SUN1 was
P = 0.009. (C) Total protein extracts from control (C) and patient MD-1 myoblasts were Western blotted using antibodies against LINC complex-
associated proteins, as indicated. (D) Samples prepared as in A were Western blotted using nesprin-2 (N2–N3) antibodies. (E–F) Protein expression
was quantified by densitometric analysis of at least 3 independent experiments. The results are presented as mean 6 S.E. *P#0.05 and **P#0.01.
Each significant P- values are as follows: SUN1 P = 0.05, a-tubulin P = 0.003, nesprin-2 P = 0.002. P- value for emerin was P = 0.06.
doi:10.1371/journal.pgen.1004605.g003
Figure 4. Emerin binding to p.G68D/p.G338S SUN1 is reduced in vivo. (A) SUN1 was immunoprecipitated from control (C) or MD-1 myoblast
soluble lysates using 2383 SUN1 antibodies and samples Western blotted to detect co-immunopreciptated proteins. (B) Densitometric analysis of
SUN1, lamin A/C and emerin bands from immunoprecipitated samples is plotted in arbitrary units (A.U.). (C) SUN1 was immunoprecipitated from
control or MD-1 myoblasts and co-precipitated nesprin-2 was detected using N2–N3 antibody. Size markers (kDa) are indicated. Note that larger
nesprin-2 isoforms are enriched in the immunoprecipitate compared to the lysate. (D) HEK293 cells were co-transfected with myc-SUN1 mutant and
GFP-emerin plasmids and harvested after 48 hours. Co-precipitated GFP-emerin was detected by immunoblotting using GFP antibodies (myc-SUN1
IP). (E) Densitometric values of immunoblotted GFP-emerin bands are reported in arbitrary units (A.U.). (F) Human fibroblasts from an EDMD2 patient
carrying the R401C LMNA mutation were transfected with SUN1-WT or SUN1-W377C cDNAs and fixed 48 hours after transfection. Lamin A/C was
labelled using specific antibodies and revealed by FITC-conjugated secondary antibody (green). SUN1 was detected using Cy3-conjugated anti-myc
antibody (red). Nuclei were counterstained with DAPI. Images show pairs of daughter cells from recent cell divisions. Increased dysmorphic nuclei
with nuclear blebbing and honeycomb structures (arrows) are observed in double-mutant cells. The distance between daughter cells has been
reduced using Photoshop 7 to allow magnification. (G) Percentage of dysmorphic nuclei in EDMD2 cells left untreated (untransfected), transfected
with WT-SUN1 or transfected with W377C-SUN1 is reported in the graph as the mean of three independent experiments. Statistically significant
differences (P,0.05) relative to controls or WT-transfected samples are indicated by asterisks.
doi:10.1371/journal.pgen.1004605.g004
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decrease in interaction with SUN1 G68D (Figure 4D–E). This
correlates with the close proximity of G338 and W377 to the
emerin binding site on SUN1 (see Figure 1A; [44]).
SUN1 W377C increases the severity of nuclear defects in
EDMD2 fibroblasts
Abnormalities in nuclear morphology and a honeycombed
pattern of protein expression at the NE are commonly observed in
EDMD fibroblasts obtained from patients with LMNA or EMD
mutations [57–59]. We did not observe any obvious defects in
nuclear morphology or protein localization in myoblasts from
patient MD-1 (Figure 3A) or in cells transiently expressing a range
of SUN1 or SUN2 mutants (for example, see Figure 2). However,
we sought to determine whether SUN1 mutants have a modifying
effect to increase the severity of nuclear defects when expressed in
combination with mutations in LMNA or EMD. To achieve this,
we expressed SUN1 W377C, found in combination with a LMNA
R453W mutation in patient MD-5, in fibroblasts obtained from an
EDMD2 patient carrying LMNA R401C. Cells expressing SUN1
W377C had a 4-fold increase in the level of nuclear dysmorphol-
ogy, in terms of increase in nuclear blebbing and formation of
honeycomb structures (Figure 4F, arrows), compared to those
expressing WT SUN1 (Figure 4F–G). Cells expressing WT SUN1
had a 2-fold reduction in nuclear abnormalities compared to
untransfected cells, suggesting a protective effect of SUN1 over-
expression.
MD-1 myoblasts exhibit an enhanced rate of
differentiation but myonuclei are disorganized
Exogenous expression of EDMD2-associated lamin A/C
variants and disruption of endogenous lamin A/C, emerin or
the LINC complex all affect myoblast differentiation [60–63].
Furthermore, studies in Drosophila indicate that the LINC
complex is required for correct myonuclear spacing [34]. We
therefore determined whether the myoblasts carrying SUN1
variants had defects in their ability to differentiate to form mature,
multinuclear myotubes. In order to account for inherent
differences in differentiation capacity between cell lines, we
compared MD-1 cultures with a total of 5 control cultures
independently established from different individuals. SUN1
staining was clearly evident at the nuclear envelope of MD-1
myotubes, as previously observed in myoblasts (Figure 5A).
However, we found that the MD-1 myoblasts exhibited an
increased rate of differentiation, both in terms of the number of
myotubes and the number of nuclei per myotube. There was a
striking increase in the percentage of nuclei within myotubes
(defined as muscle-specific caveolin3-positive cells containing at
least 3 nuclei) in patient cultures (2866% versus 5869% in
control and MD-1 cultures, respectively; mean 6 sem) and a 5-
fold increase in myotubes possessing more than 10 nuclei
(Figure 5A–E). Strikingly, 45% of these myotubes displayed gross
nuclear misalignment and clustering, with up to 30 nuclei per
myotube in some instances (Figure 5D,F).
Together with our earlier observation of defective nuclear
repositioning in fibroblasts expressing disease-associated variants
and in double-mutant EDMD2 fibroblasts, these findings suggest-
ed that mutations in SUN1 and SUN2 disrupt connections with
the cytoskeleton, thereby perturbing nuclear anchorage. Studies
have previously shown that SUN1 and SUN2 become concen-
trated at the poles of the nucleus during human primary myoblast
differentiation and that this polarization is linked to correct
myonuclear spacing [32]. We therefore examined SUN1 and
SUN2 polarization in patient MD-1 myotube nuclei and found
that, whilst SUN1 polarization was normal (Figure S5), SUN2
failed to polarize in clustered nuclei (Figure 5D,G). In keeping
with earlier observations in myoblasts, we also found that nesprin-
2 fluorescence intensity was significantly increased in all patient
myotubes (Figure S6). Ultrastructural analysis showed that myo-
nuclear clustering occurred within single MD-1 myotubes
(Figure 5H) and further demonstrated that enlarged highly
differentiated myotubes with misaligned nuclei were devoid of
detectable sarcomeric structures that were visible in controls
(Figure 5H, arrowheads).
Pericentrin recruitment and microtubule nucleation at
the NE is defective in MD-1 myotubes
During myotube formation, the microtubule network is
reorganized into a parallel array along the longitudinal axis of
the myotube and is nucleated from the nuclear surface, which
becomes the primary microtubule organizing centre (MTOC) of
the cell [64]. As part of this process, centrosomes undergo partial
disassembly and centrosomal proteins, including c-tubulin,
pericentrin and PCM-1, become concentrated at the nuclear
periphery [65,66]. We hypothesized that SUN proteins contribute
to centrosomal protein recruitment to the NE and that polariza-
tion of SUN proteins at the nuclear poles may promote linear
nuclear organization in myotubes. We therefore investigated the
recruitment of centrosomal proteins to the NE during myogenesis,
using pericentrin as a marker. In control myotubes we found that
pericentrin was recruited to the NE and there was a suggestion
that it concentrated at the poles of the nuclei, in a similar manner
to SUN2 (Figure 6A). In contrast, pericentrin failed to accumulate
to any significant degree at the nuclear surface in MD-1 myotubes
and was instead found in cytoplasmic foci. These findings support
our hypothesis that SUN proteins are involved in the recruitment
of pericentrin to the NE in myotubes.
We next investigated whether microtubule nucleation from the
NE was disrupted in the patient myotubes by observing
microtubule regrowth following nocodazole-induced depolymer-
ization. In control cells, microtubules could be clearly observed
emanating from around the nuclear surface after nocodazole
wash-out for 30 minutes (Figure S7). In contrast, the microtubule
network in patient cells was very disorganized and often did not
appear to be attached to the NE, suggesting a defect in
microtubule nucleation, anchoring or organization. To investigate
this further, we performed a short 5-minute nocodazole wash-out
to detect sites of microtubule nucleation. Microtubule asters
regrowing from the nuclear envelope were observed in control
myotubes (Figure 6B, panel a) and committed myoblasts (Fig-
ure 6B, panel b). Microtubule nucleation correlated with sites of
pericentrin concentration at the nuclear poles (arrows in
Figure 6B). In MD-1 myotubes and committed myoblasts,
microtubules were seen to nucleate mainly from multiple sites in
the cytoplasm, corresponding with the locations of cytoplasmic
pericentrin foci (Figure 6B, arrowheads). Counting fifty myotubes
per sample, we could demonstrate that the mean number of
microtubules nucleating from myotube nuclei was significantly
reduced in MD-1 (Figure 6D).
These data suggested that centrosome attachment to the
nucleus may also be disrupted in myoblasts from this patient.
We therefore examined nuclear-centrosomal distance in MD-1
myoblasts and indeed observed a 2-fold increase in separation
between the nucleus and centrosomes in the patient myoblasts
compared to controls (mean distance 4.34 mm versus 2.07 mm,
respectively) (Figure 6C,E).
To confirm that loss of pericentrin recruitment to the NE was a
direct consequence of SUN1 mutation, we observed pericentrin
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Figure 5. Enhanced rate of differentiation, nuclear misalignment and clustering in MD-1 myotubes. (A) Immunofluorescence staining of
MD-1 myotubes using SUN1 (green) and desmin antibodies (red). Chromatin was stained with DAPI (blue). Scale bar, 30 mm. (B) Graphical
representation of the percentage of nuclei within myotubes counted in MD-1 and in five independent control cultures. (C) Phase contrast image of
living control and MD-1 cultured myotubes (arrows) showing myonuclear clustering in patient cells. Scale bar, 10 mm. (D) Immunofluorescence
staining of control and MD-1 myotubes with SUN2 (green) and caveolin 3 (red) antibodies. Arrows indicate SUN2 polarization at the nuclear poles in
control cells. (E–F) Graphical representation of the percentage of myotubes with more than 10 nuclei and the percentage of myotubes with
myonuclear clustering in control and MD-1 cultures. Data are presented as mean values 6 S.D. of three independent experiments (50 myotubes per
sample were counted). (G) Graphical representation of the percentage of committed myoblast and myotube nuclei with enrichment of SUN2 staining
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localization in C2C12 myotubes following transient transfection with
myc-SUN1 variants. Pericentrin was absent from the NE of
myonuclei expressing SUN1 G68D, G338S and W377C variants,
but exhibited clear nuclear rim staining in myonuclei expressing WT
SUN1 (Figure 7 A–B). Thus, all 3 mutants tested acted in a dominant
manner in C2C12 cells to displace pericentrin from the NE.
Finally, to directly link the SUN1 mutants to the nuclear
clustering phenotype observed myotubes of patient MD-1, we
assessed the degree of nuclear clustering in myotubes expressing
WT SUN1 and the G68D, G338S and W377C variants. Whilst
22% of myotubes expressing WT SUN1 displayed myonuclear
clustering, this value was increased by 2-fold in the cultures
at the nuclear pole(s). Data are presented as mean values 6S.D. of 3 independent experiments (200 nuclei per sample). (H) Transmission electron
microscopy analysis of control and MD-1 myotubes (see Materials and Methods for details). Sarcomeric structures are evident in control myotubes
(arrowheads), whereas they are absent from MD-1 myotubes showing myonuclear clustering. Arrows indicate myonuclei. Scale bar, 10 mm.
doi:10.1371/journal.pgen.1004605.g005
Figure 6. Impaired pericentrin localization and microtubule nucleation at the nuclear envelope in MD-1 myotubes. (A) Beta-tubulin
(red) and pericentrin (green) double immunofluorescence staining of control and MD-1 myotubes. Chromatin was stained with DAPI (blue). Scale bar,
10 mm. Arrows indicate apparent pericentrin accumulation at the nuclear poles. (B) Control and MD-1 myotubes were treated with nocodazole
followed by 5 min recovery in culture medium to allow microtubule regrowth. Samples were then fixed and stained as in panel A. Panels a and c
show myotubes, whilst panels b and d show committed myoblasts from control and MD-1 cultures, respectively. Arrows in control cells indicate sites
of microtubule regrowth at the nuclear poles, co-inciding with pericentrin localization. Arrowheads in patient cells indicate microtubule regrowth
from cytoplasmic pericentrin foci. (C) Control and MD-1 myoblasts were fixed in methanol and subjected to immunofluorescence analysis using c-
tubulin antibodies to stain the centrosome and DAPI to stain the DNA. Distances between centrosomes and the nuclear periphery (mm) are indicated.
Scale bar, 10 mm. (D) The number of microtubules nucleating from individual myotube nuclei prepared in B was counted and is presented as the
mean 6S.D (n = 50 nuclei per sample). * p,0.05 as calculated using the Student’s t-test. (E) Nucleus-centrosome distance was measured in 100
control and MD-1 myoblasts prepared in C, in two independent experiments, using Leica LAS AF Lite software and analysed using SPSS software. The
median values (thick black lines) were 0.96 and 2.43 mm for control and MD-1 cells, respectively. P = 0.00012. # and * correspond to mild and extreme
outliers, respectively.
doi:10.1371/journal.pgen.1004605.g006
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expressing each of the 3 SUN1 variants (Figure 7C). These
findings confirm that the SUN1 p.G68D and p.G338S mutations
are the primary cause of the failure to recruit pericentrin to the NE
and the defective nuclear positioning in myotubes from patient
MD-1 and further indicate that this is likely to be common to
muscle from patients carrying other SUN1 mutations, including
p.W377C.
In summary, our data demonstrate that muscle disease-associated
alterations in SUN proteins result in loss of nuclear connectivity to
the cytoskeleton. In myotubes, SUN1 mutations disrupt connec-
tions with centrosomal components and the microtubule network,
in particular impairing microtubule organization and nucleation
from the NE. This in turn is likely to lead to impaired myonuclear
positioning in multinuclear myotubes, which we propose may be an
important contributor to muscle dysfunction.
Discussion
We have identified a total of 11 SUN1 and 7 SUN2 rare, non-
synonymous variants in our cohort of EDMD and related
myopathy patients. Ten of these variants, identified in nine
unrelated families, had putative pathogenic effects as deduced
from genetic and functional analyses.
Multiple modes of inheritance of SUN1 and SUN2
mutations
Our data add to an increasingly complex picture concerning the
genetics of EDMD and related myopathies, where multiple genes,
either alone or in combination, can cause or modify the disease
phenotype. The SUN1 and SUN2 variants appear to be inherited
in highly variable manners, with or without the presence of a
mutation in a second gene. In 2 families (families 1 and 2), SUN1
or SUN2 variants were inherited from each of the unaffected
parents of the index patients, strongly supporting an autosomal
recessive mode of inheritance in those families. One sporadic case
carried heterozygous mutations in both the SUN1 and SUN2
genes, suggesting that mutations in the 2 genes could have additive
effects, as has been observed in Sun1/Sun2 knockout mice [30]. In
other instances, the index case carried only one SUN1 or SUN2
Figure 7. Exogenously expressed SUN1 mutants impair pericentrin recruitment to the nuclear envelope. (A) Differentiated C2C12
myotubes transfected with wild-type (WT) SUN1, or the indicated mutants, were labelled with anti-myc (red) and anti-pericentrin antibodies (green).
Desmin antibody (violet) was used as a muscle differentiation marker. Nuclei were counterstained using DAPI. Samples were observed using a Nikon
laser confocal microscope. Bar, 10 mm. (B–C) Transfected myotubes prepared as in A were quantified for the absence of pericentrin staining at the
nuclear envelope (B) and myonuclear clustering (C). Thirty myotubes per sample were counted in two independent experiments. Differences for all
mutants were statistically significant with respect to wild-type-transfected myotubes (P,0.01).
doi:10.1371/journal.pgen.1004605.g007
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variant and often represented a sporadic case, suggestive of either
a dominant de novo mutation or presence of a concurrent
mutation in another, as yet unidentified, gene.
We also identified SUN1 or SUN2 variants in individuals from
4 families harbouring known LMNA or EMD mutations. In all
cases, the SUN1/SUN2 mutation alone did not cause disease in
other family members. However, disease severity was significantly
increased in the individuals carrying both mutations compared to
family members, or unrelated individuals, carrying only the
LMNA or EMD mutation. Furthermore, their phenotype was on
the severe end of the spectrum, as defined by Yates et al. [50].
These findings suggest that some SUN1/SUN2 variants act as
modifiers to increase disease severity. There has been much
speculation as to the existence of modifier genes in EDMD due to
high variability in disease phenotype between affected individuals
within families [37,38,41,47] and there is now some evidence to
support this. In a family with X-linked EDMD caused by an EMD
p.Y105X mutation, disease severity was increased in one
individual due to a second mutation present in the LMNA gene
[42]. Similarly, an individual with severe disease and carrying a
LMNA p.R644C mutation was found to carry a second mutation
in the gene encoding desmin [42].
In our cohort, for some cases (such as patient MD-3) the
increased severity was expressed as clinically more severe muscular
dystrophy [39]. In other cases, the additional presence of a SUN1/
SUN2 mutation was associated with more severe cardiac disease.
For example, patient MD-5 from family 5, carrying both LMNA
p.R453W and SUN1 p.W377C mutations, developed cardiac
disturbances at age 25 and died from heart failure at age 34, which
is much earlier than is typical for EDMD patients [50].
Furthermore, LMNA p.R453W is a relatively common mutation
that has been reported in at least 15 individuals with EDMD and is
usually associated with mild disease [8,48,67–70]. Thus, it is likely
that the SUN1 mutation carried by patient MD-5 contributed to
their increased disease severity. We also identified SUN1
p.W377C in combination with SUN2 p.E438D in a sporadic
case, supporting the idea that a mutation in a second gene is
required for disease causation in this instance. Further support for
a modifying role for the p.W377C mutation came from the ability
of this mutant to worsen nuclear dysmorphology when expressed
in LMNA R401C patient fibroblasts.
Individuals MD-6 and MD-7 (carrying a SUN2 variant in
addition to LMNA T528K and R99P mutations, respectively) also
had more severe disease than is typical for EDMD, with early
onset at age 1 and 4 years, respectively, and unusually early
requirement for heart transplantation. In each of these sporadic
cases, the LMNA mutation arose de novo and so no comparisons
can be made with family members, however, their clinical
phenotype is consistent with the suggestion that the SUN2
variants contribute to increased disease severity. Whilst our genetic
and cell-based data strongly support a modifying role for SUN
mutations in some patients, studies involving larger patient cohorts
will be necessary to prove this conclusively.
For 8 of the rare, non-synonymous variants identified in our
cohort, there was a lack of compelling evidence of their disease
association. However, given the complex interplay between muta-
tions in different genes, more investigation is required before entirely
ruling out their involvement. In particular, SUN1 p.V846I was found
in an isolated sporadic case and thus no co-segregation analysis could
be performed to support its disease association. Yet this is a mutation
of highly conserved residue (Figure S3) that lies within the SUN
domain that is involved in nesprin binding. Thus it will be important
in the future to utilize functional studies to investigate the impact of
such mutations on LINC complex interactions.
Despite our findings increasing the number of known EDMD-
associated genes to 8, still almost 50% of patients in our cohort
have no identified mutations in any of these genes. Most of these
patients represent sporadic cases, with no family history of disease,
making mutation screening difficult. Furthermore, since 6 of the
known genes each account for only a small percentage of cases, it
is likely that there are multiple genes remaining to be identified.
Proteins associated with the LINC complex are clearly very strong
candidates and there are several such proteins that should be
examined as a priority, including Samp1 [71,72].
Muscular dystrophy-associated SUN1 and SUN2 variants
disrupt nuclear-cytoskeleton connection and nuclear
positioning
Through the various nesprin isoforms expressed at the ONM,
the LINC complex mediates attachment to all three cytoskeletal
filament networks [17,73]. In this study, we have demonstrated, in
several different systems, that muscular dystrophy-associated
mutations in SUN1 or SUN2 impair nuclear coupling to the
both actin and microtubule networks and disrupt nuclear
movement and positioning.
In mouse NIH3T3 fibroblasts, five out of the six SUN1 and
SUN2 variants that we examined inhibited rearward movement of
the nucleus, which has previously been shown to be achieved
through LINC complex attachment to actin cables closely
associated with the nuclear surface [53]. Our data strongly
indicate that at least five of the variants identified in our patient
cohort have a negative functional impact upon nuclear-cytoskel-
etal connection via the LINC complex, which is likely to be a
major contributor to muscle disease pathophysiology. One of the
variants examined, SUN2 p.M50T, did not impair rearward
nuclear movement, suggesting that this variant is not disease-
causing and this is entirely possible given the complex genetics in
the individual carrying this mutation (patient MD-2). In agree-
ment with our findings, EDMD-associated lamin A variants were
recently shown to cause a similar defect in nuclear movement in
NIH3T3 cells [52] and disrupted nuclear-cytoskeletal coupling
[74].
We also observed defects in nuclear positioning in differentiat-
ing myotubes derived from patient MD-1, carrying compound
heterozygous SUN1 p.G68D/p.G338S mutations, which is
consistent with recent findings that proper SUN1 and SUN2
recruitment to the NE is required for myonuclear spacing [32]. In
strong support for a direct role of SUN proteins, nuclear
positioning in skeletal muscle is disrupted in double Sun1/Sun2
knockout mice or in mice with targeted disruptions of nesprin-1/
nesprin-2 and this leads to clustering similar to that observed in
our patient myotubes [30,31,75]. Thus, the phenotype we
observed in patient MD-1 is consistent with a defect in the LINC
complex. Several recent studies have shown that myonuclear
position is controlled by nuclear attachment to the microtubule
network and that this is mediated by the LINC complex
[34,35,76–78]. At the onset of myoblast differentiation, proteins
involved in microtubule nucleation redistribute from the centro-
some to the NE. Our observations of impaired pericentrin
recruitment and microtubule nucleation/organization at the NE
in the patient myotubes therefore support a model whereby
mutations in SUN proteins impair nuclear-microtubule connec-
tion and prevent correct positioning of myonuclei (Figure 8). It is
also well established in other systems that unanchored nuclei float
freely in the cytoplasm and tend to clump together, as observed in
MD-1 myotubes [34,77,79].
It is currently not clear how the mutant SUN proteins, which
are located at the INM, mediate disruption of microtubule
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attachment to the NE. Studies have indicated that nesprins are
important for microtubule association with the NE, through their
interaction with microtubule motor proteins [77,80]. However, we
did not obtain any evidence that the central SUN1-nesprin-2
LINC complex interaction was perturbed in MD-1 myoblasts,
suggesting that the defect may lie elsewhere. Instead, SUN1
interaction with emerin was disrupted and, consistent with this,
both emerin mRNA and protein levels were reduced in myoblasts
from patient MD-1. Impairment of SUN1/SUN2 interaction with
emerin has also been observed in cases of EDMD1 due to
mutations in emerin itself [44]. Furthermore, EDMD has been
associated with defects in emerin interaction with lamin A/C and
nesprins [18,19]. Interestingly, emerin has been shown to partially
localize at the ONM, where it may contribute to centrosomal
attachment to the NE and, in agreement with our findings, others
have observed increased centrosomal separation from the nucleus
in EDMD1 cells [81,82]. Thus, dysregulation of emerin may play
a role in disease causation.
Contribution of SUN mutations to muscle disease
pathophysiology
To date, most studies have focused on the role of the nuclear
lamina and LINC complex in cellular resistance to mechanical
strain in support of the ‘‘structural’’ hypothesis of laminopathy
disease causation. There is now strong evidence to indicate that
defects in these structural networks make a significant contribution
to the pathophysiology of EDMD and related disorders [29].
Given our observations of defective interaction networks in SUN-
mutated cells and uncoupling of nuclear-cytoskeletal connections,
it is therefore likely that the variants we have discovered in SUN1
and SUN2 also impact upon cell mechanics. Nuclear dysmor-
phology is a common feature of laminopathy cells and, whilst the
exact cause and effect of this phenomenon is not understood, it is
likely to reflect changes in the organization of the nuclear lamina
and its interactions with the nuclear envelope [83], together with
increased susceptibility to mechanical deformation. The exacer-
bation of nuclear dysmorphology, induced by SUN1 W377C
expression in LMNA R401C fibroblasts, again highlights a role for
SUN proteins in NE organization and integrity.
Our findings in patient MD-1 myotubes further indicate that
defects in nuclear positioning may play a significant role in disease
pathogenesis, particularly since a link has also been made between
loss of myonuclear anchoring and impaired muscle function
[34,35]. Myonuclear positioning defects have been observed at the
myotendinous junctions of LmnaH22P/H22P and Lmna knock-out
mice, and in EDMD patients with mutations in LMNA [33,84].
However, to our knowledge, ours is the first observation of such a
pronounced myonuclear mispositioning phenotype in humans. It
will be important, in future studies, to demonstrate directly that
uncoupling of the nucleus from the microtubule network through
SUN mutation does lead to muscle disease in vivo with
physiological expression levels of SUN mutants.
In summary, our data clearly implicate defects in pericentrin
recruitment, microtubule nucleation/organization and nuclear-
cytoskeletal attachment in NE-associated muscular dystrophy
pathogenesis and are in agreement with the bulk of results
showing SUN1/SUN2 involvement in nuclear positioning and cell
migration. It remains to be determined precisely how centrosomal
components are recruited to the nuclear envelope in differentiating
myotubes and how defects in this process result in misalignment of
myonuclei in muscular dystrophy.
Materials and Methods
Ethics statement
This study involved the use of human DNA samples and myoblasts
derived from muscle biopsies. These were obtained following
informed consent using protocols and consent forms approved by
the Ethics Committee of Ernst-Moritz-Arndt University, Greifswald.
Patients and controls
EDMD patients for this study were selected based on the results
of a routine diagnostic mutational analysis of EMD, LMNA, FHL1,
SYNE1 and SYNE2. 175 pseudo-anonymized patients negative for
mutations in these genes and 70 patients known to carry mutations
in the genes encoding the LINC components emerin, lamin A/C
and nesprin 1 or 2 alpha and beta were tested for mutations in
SUN1 and SUN2. The clinical features of these unrelated,
predominantly Caucasian index cases were within the diagnostic
criteria for EDMD [50] despite the variable clinical expression.
Mutation analysis
Primer pairs for all the coding exons and flanking intronic
sequences of SUN1 (UNC84A, ENSG00000164828; see Fig. S1)
Figure 8. Schematic model of nuclear positioning and microtubule connections during differentiation of normal and SUN1/2
mutant myoblasts. (A) In myoblasts, the close positioning of centrosomes (red) to the outer nuclear surface is disrupted by SUN1/2 mutants, which
is likely to be accompanied by impaired microtubule (green) association with the NE. (B) Upon commitment to differentiation in normal myoblasts,
pericentrin and other centrosomal proteins redistribute from the centrosome to the nuclear surface, which becomes the major site of microtubule
nucleation. In mutant committed myoblasts, pericentrin fails to associate with the NE and there is impairment of microtubule nucleation from the
nuclear surface. (C) After cell fusion to form myotubes, the microtubules reorganize into overlapping parallel arrays along the long axis of the cell.
The myonuclei become positioned evenly along the length of the cell in a microtubule-dependent manner with the involvement of dynein and
kinesin motor proteins. In mutant myotubes, nuclei are clumped in a disorganized fashion and we propose that this is due to an inability to interact
with the microtubule network.
doi:10.1371/journal.pgen.1004605.g008
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and SUN2 (UNC84B, ENSG00000100242, ENST00000405510)
were designed using Primer-Blast (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/index.cgi; Table S2). To standardize the
sequencing reaction, all primers were tagged with an M13-tail
(forward: 59-GTAAAACGACGGCCAGT-39 reverse: 59-CAG-
GAAACAGCTATGAC-39). Amplifications were performed in
25 ml volumes using Amplikon-Taq Polymerase (Biomol) under
the following thermal conditions: initial denaturation at 94u for
5 min followed by 35 cycles of denaturation (94uC for 15 sec),
annealing at the appropriate temperature for 15 sec (see Table S2)
and elongation (72uC for 1 min). A final elongation (72uC for
7 min) preceded a 4uC cooling step
Direct Sanger sequencing was used to analyse PCR products.
Excess dNTPs and primers were removed using ExoSAP-IT
(Affymetrix). Sequencing reactions were performed using ABI
BigDye Terminator v3.1 Cycle Sequencing Kit with addition of
5% DMSO to the reaction mix. M13-oligonucleotides were used
as sequencing primers. The reactions were analysed on a 3130xl
GA DNA Sequencer (Applied Biosystems) according to the
manufacturer’s instructions. All DNA variations identified were
validated using a second independent DNA sample.
Analysis of the frequency of DNA variations
Unique and rare sequence variations were tested for their
frequency in 400 alleles of a Caucasian reference population.
Additionally, sequence variations found in a patient of Turkish
origin were tested in 138 alleles of a Turkish reference population.
Co-segregation of DNA variations with the disease was analysed in
patient families if available. For estimating the frequency of DNA
variations found, restriction digestion and high resolution melting
(HRM) were performed using patient DNA as positive control.
Restriction enzymes cutting specifically at the DNA variation were
selected using NEB-cutter (http://tools.neb.com/NEBcutter2/).
HRM products amplified with LightCycler 480 High Resolution
Melting Master (Roche) were analysed on a LightCycler 480 II
(Roche) according to the manufacturer’s instructions. Samples
showing abnormal signals were examined by restriction endonu-
clease digestion or direct sequencing. The frequency of changes
found in patients of different origin was estimated from online
accessible genome sequencing data (Table S1).
Real-time PCR
RNA was extracted from patient MD-1 and control myoblasts
using TRIzol (Invitrogen) according to the manufacturer’s
instructions. Real-time PCR was performed using a RealTime
ready custom panel and LightCycler 480 Probes Master (Roche),
with primers as described in Supplementary Material Table S3,
and evaluated on a LightCycler 480 II (Roche), according to the
manufacturer’s instructions. Values for each gene were normalised
to both actin and GAPDH.
Plasmid constructs and site-directed mutagenesis
For plasmid constructs, the pCMVTag3B vector (Stratagene)
was used to fuse a myc tag to the N-terminus of SUN1. The 916
amino acid version of the SUN1 cDNA, lacking the ATG start
codon, was generated by PCR amplification in two stages. First,
codons 2–362 were amplified using primers 59-CACAGAATTC-
GATTTTTCTCGGCTTCACAT-39 and 59-CACAGTCGA-
CCTATCCGATCCTGCGCAAGATCTGC-39 with IMAGE
clone 40148216 as template and inserted into pCMVTag3B via
the EcoRI and SalI sites. This introduced a BglII site via a silent
mutation at codon 356–358. Codons 352–916 were then amplified
using 59-TTACTTCTTGCTGCAGATCTTGCGCAGGAT-
CGG-39 and 59-GAGAGTCGACTCACTTGACAGGTTCGC-
CATG-39 from an oligo dT-primed reverse transcription of U2OS
cell mRNA and cloned into the BglII-SalI sites of the initial
construct. EDMD-associated mutations were introduced using the
QuikChange II site-directed mutagenesis kit (Stratagene), accord-
ing to the manufacturer’s instructions.
Antibodies
Anti-human SUN1 2383 and anti-human SUN2 2853 antibod-
ies have been described previously [44]. Anti-SUN1 Atlas
antibody (HPA008346) was obtained from Sigma prestige
antibodies. Anti-nesprin-2 (N2N3) antibody was kind gift from
Q. Zhang (King’s College London) and has been described
previously [16]. Anti-nesprin-2G has been reported previously
[53]. Anti-nesprin-2 monoclonal antibody (IQ562) was purchased
from Immuquest. Monoclonal anti-emerin antibody was a kind
gift from G. Morris (Center for Inherited Neuromuscular Disease,
Oswestry, UK). Anti-lamin A/C (sc-6215) and GFP antibodies
were purchased from Santa Cruz Biotechnologies. Anti- GAPDH
(MAM374) was obtained from Millipore. Anti-a-tubulin (T9026),
anti-b-actin (A5441), anti-c-tubulin (T6557), anti-myc and anti-
desmin antibodies were purchased from Sigma. Anti-caveolin 3
monoclonal antibody (610420) was purchased from Transduction
Laboratories and anti-desmin polyclonal antibody (MONX10657)
was purchased from Monosan. Anti-pericentrin polyclonal anti-
body (Ab4448) was obtained from Abcam.
Cell culture and transfection
Myoblasts from patient MD-1 and controls were routinely
cultured in high-glucose DMEM supplemented with 20% foetal
bovine serum plus antibiotics penicillin, streptomycin and
amphotericin B, at 37uC and 5% CO2, and were used between
passages 3 and 7. Myoblasts at confluence were allowed to
differentiate into myotubes in the same culture medium for 8–15
days, replacing the medium every 5 days. HeLa cells were cultured
in DMEM supplemented with 10% FBS and antibiotics. For
emerin co-immunoprecipitation experiments, HEK293 cells were
transfected with the appropriate pCMVTag3-SUN1 constructs
together with GFP-emerin [85] using Fugene 6 (Promega),
according to the manufacturer’s instructions. pCMVTag3-SUN1
constructs were transfected into C2C12 mouse myotubes using the
Amaxa Nucleofector (Lonza), according to the manufacturer’s
instructions. Cultures were fixed 24 hours after transfection and
processed for immunofluorescence analysis.
Centrosome reorientation and nuclear movement assay
NIH3T3 fibroblasts were cultured in 10% calf serum in DMEM
(Gibco) as previously described [86]. Following serum starvation
for two days, confluent monolayers were ‘‘wounded’’ by removing
a strip of cells and nuclei of cells at the edge of the wound were
microinjected with the appropriate myc-tagged SUN1 or SUN2
DNA plasmids. After expression for 2 hr, cells were stimulated
with 10 mM LPA for 2 hr, fixed in 4% paraformaldehyde,
extracted with Triton X-100 and stained with antibodies to
tyrosinated a-tubulin (rat monoclonal antibody at 1/40 of culture
supernatant), myc (mouse monoclonal antibody from clone 9E10,
Roche) and DAPI (Sigma) followed by appropriate secondary
antibodies. Stained samples were observed with a Nikon TE300
microscope using a 406 Plan Apo N.A. = 1.0 or 606 Plan-Apo
N.A. = 1.4 objective and filter cubes optimized for DAPI,
fluorescein/GFP, and rhodamine. Images were acquired with
CoolSNAP HQ camera (Photometrics) driven by Metamorph
software (MDS Analytical Technologies) and further processed in
Image J. Centrosomes were considered oriented if they were
localized in the pie-shaped sector between the nuclear membrane
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the leading edge scored, as described [86,87]. Random orientation
is ,33% by this measure. Nuclear and centrosome position
relative to the cell centroid were determined as described [88].
Data were plotted as % of the cell radius to normalize for
differences in cell size.
Cell extracts, immunoprecipitation, and immunoblotting
To prepare total cell extracts for immunoblotting, cells were
scraped into cold 16phosphate-buffered saline (PBS), pelleted by
centrifuging at 2006g for 5 min and then pellets were resuspended in
lysis buffer (10 mM HEPES [pH 7.4], 5 mM EDTA, 50 mM NaCl,
1% Triton X-100, 0.1% SDS) supplemented with 1 mM PMSF and
protease inhibitor cocktail (Roche) and an equal volume of Laemmli
buffer was then added. For human myoblast immunoprecipitations,
cells were grown on 10 cm dishes and then immunoprecipitated as
described previously (Haque et al., 2006) using 2 mg of SUN1 2383
antibody. 5% of the initial lysate was retained for immunoblot
analysis. All samples were boiled in an equal volume of 26Laemmli
buffer, resolved on 6% or 7.5% or 10% polyacrylamide gels, followed
by semidry transfer onto nitrocellulose membrane. Membranes were
probed using the appropriate primary antibodies and dilutions:
hSUN1 ATLAS (1:400), hSUN2 2853 (1:500), lamin A/C (1:2000),
emerin (1:1500), nesprin-2 N2N3 (1:1500), a-tubulin (1: 10,000), b-
actin (1:20,000), GAPDH (1: 10,000). Primary antibodies were
detected using horseradish peroxidase-conjugated secondary antibod-
ies (Sigma), and visualization was performed using ECL reagents
(Geneflow).
Indirect immunofluorescence microscopy
Myoblasts and myotubes grown on glass coverslips were fixed in
methanol at 220uC and processed for indirect immunofluorescence
microscopy as previously described (Haque et al., 2006). For SUN1
staining, cells were instead fixed in 4% paraformaldehyde and
permeabilized with 0.5% Triton X-100 at room temperature for
5 min. Cells were washed in PBS and incubated with antibodies
diluted in PBS–3% bovine serum albumin, using hSUN1 2383 (1:150),
hSUN2 2853 (1:100), lamin A/C (1:400), emerin (1:500), nesprin-2G
(1:300), c-tubulin (1:500) pericentrin (1:50), caveolin 3 (1:30) and
desmin (1:100) antibodies. Secondary antibodies were goat anti-rabbit
AlexaFluor 488, donkey anti-mouse AlexaFluor 594 and donkey anti-
goat AlexaFluor 594 (Molecular Probes Inc.). DNA was stained with
50 mg/ml 49,6-diamidino-2-phenylindole (DAPI; Sigma). Coverslips
were mounted in 80% glycerol–3% n-propyl gallate (in PBS) or
ProLong gold antifading reagent (Invitrogen). Fluorescence microscopy
was performed with a Nikon TE300 inverted microscope with an
ORCA-R2 charge-couple device camera (Hamamatsu) and Volocity
software (PerkinElmer). Where required fluorescence microscopy was
also performed with Leica TCS SP5 confocal laser scanning
microscope and Leica LAS AF software. Images were processed with
Adobe Photoshop (Adobe Systems). Quantification of fluorescence
intensity was performed using an Olympus Scan‘R microscope with a
206 objective. Approximately 1000 nuclei from 3 independent
experiments were randomly selected by their DAPI signal, and the
intensity of SUN1, SUN2, emerin, lamin A/C and nesprin-2 was
measured within the DAPI-stained region.
Electron microscopy
Myotubes (at passage 2–3) from patient and age-matched
controls were fixed in 2.5% glutaraldehyde-0.1 M cacodylate
buffer pH 7.4 for 3 h at 4uC. After post-fixation with 1% osmium
tetroxide (OsO4) in cacodylate buffer for 2 h, samples were
dehydrated in an ethanol series, infiltrated with propylene oxide
and embedded in Epon resin. Ultrathin sections (60 nm thick)
were stained with uranyl acetate and lead citrate (10 min each)
and were observed at 0u tilt angle with a Geol Jem 1011
transmission electron microscope, operated at 100 kV. At least 30
myoblasts/myotubes per sample were observed.
Statistical analysis
In all cases, statistical analysis was performed using a Student’s
t-test to compare differences in values obtained for patient/mutant
versus control samples.
Supporting Information
Figure S1 Transcript variant of SUN1 used in this study. (A)
The 23-exon SUN1 isoform used for our investigations contained
exons 4 to 26 of ENST00000456758. The start codon used is the
same used in isoform ENST00000405266. (B) The resulting
isoform encodes 916 residues and corresponds to the full length
mouse isoform of SUN1 that predominates in most tissues [89].
Alternating exons are indicated in black and blue. Residues
spanning splice sites are indicated in red.
(TIF)
Figure S2 Pedigrees of MD families with index patients carrying
heterozygous SUN1 or SUN2 variants that do not co-segregate with
disease. Index cases are indicated by arrows. There was no evidence of
increased disease severity in the index cases carrying the SUN1
variants.
(PDF)
Figure S3 Evolutionary conservation of SUN1 and SUN2
mutated residues. All rare, non-synonymous variants identified
in SUN1 and SUN2 are shown. Those for which there is strong
genetic and/or functional evidence of disease-association are
indicated in red. The mutated residues and their equivalents in
other species are highlighted in beige.
(PDF)
Figure S4 SUN1 mRNA levels are not altered in MD-1
myoblasts. Expression level of the indicated genes was assessed
by quantitative real-time PCR using total RNA isolated from
control and MD-1 myoblasts. Values are expressed relative to two
control genes, ACTB and GAPDH, and show the average of 2
independent experiments performed in duplicate 6S.E. Signifi-
cant P-values are as follows: SUN2 P = 0.019, LMNA P = 0.009,
SYNE1 P = 0.0016, SYNE2 P = 0.01.
(PDF)
Figure S5 SUN1 can polarize in MD-1 myotubes. SUN1 (green)
and caveolin (red) immunofluorescence staining in control and
patient MD-1 myotubes, along with DAPI (blue) staining of DNA.
Arrowheads indicate nuclei in which SUN1 is enriched at the
poles.
(TIF)
Figure S6 Nesprin-2 expression is elevated in patient MD-1
myotubes. (A) Nesprin-2 staining in myotubes from control and
patient MD-1. Immunofluorescence labeling was performed with
nesprin-2 monoclonal (red) and desmin (green) antibodies. Desmin
was used as a muscle cell marker. (B) Nesprin-2 fluorescence
intensity was measured using the NIS software analysis system and
50 myotubes per sample were analysed. Data are presented as
mean value 6S.D. Significant P-value for patient MD-1 was
0.042. Scale bar, 10 mm.
(TIF)
Figure S7 The number of microtubules nucleating from the
nuclear envelope is reduced in MD-1 myotubes. Beta-tubulin (red)
and pericentrin (green) double immunofluorescence staining in
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untreated control and MD-1 myotubes, or following nocodazole
treatment and 30 min recovery in culture medium. Chromatin
was stained with DAPI (blue). Scale bar, 10 mm. Higher
magnification (36) of nuclear envelopes in nocodazole-treated
cells is shown on the right of each picture.
(TIF)
Table S1 Single nucleotide changes found in coding regions of
SUN1 and SUN2 and their frequencies in sequenced genome
databases. Rare, non-synonymous variants are highlighted in bold,
with blue shading. *Patient MD-1 was of Turkish origin, therefore
150 alleles from ethnically matched controls were also screened for
mutations p.G68D and p.G338S.
(PDF)
Table S2 Primer sequences and annealing temperatures for
genomic amplification of SUN1 and SUN2 exons.
(PDF)
Table S3 Primers used for real-time PCR.
(PDF)
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